More recently, some bromodomain inhibitors with the capacity to targeting epigenetic readers of the BRD family, have been shown to synergistically induce apoptosis when combined to venetoclax, palbociclib, or panobinostat, in BTK wild-type, ibrutinib-resistant MCL cell lines characterized by the overexpression of antiapoptotic molecules like BCL-2, BCL-XL, XIAP, or with increased levels of CDK6 or AKT [162]. The gene discussed is BCL2; the disease is mantle cell lymphoma.